The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
Increases speed to market for drug developers working on nucleic acid therapeutics
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
These initiatives will strengthen the company’s capital base, providing financial flexibility for future
The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements.
Consequent to this appointment, Sarosh Shetty ceases to be Interim CEO of ICH.
Nadda chairs Joint Strategy Meeting with Line Ministries for TB Mukt Bharat Abhiyan- 100-Day Intensified Campaign
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
The order, part of an international framework agreement is to be executed between February to April, 2025
Subscribe To Our Newsletter & Stay Updated
